Business Wire

ADVA

1.6.2022 09:02:07 CEST | Business Wire | Press release

Share
ADVA launches GPS-backup-as-a-service to help service providers combat GNSS cyberattacks

ADVA (FSE: ADV) today announced that it’s enabling service provider customers to offer GPS/GNSS-backup-as-a-service (GBaaS). A wide range of industries are increasingly reliant on satellite-delivered timing, but with threats including jamming and spoofing cyberattacks on the rise, operators need to find ways to safeguard services that rely on positioning, navigation, and timing (PNT) information. In-network timing based on NTP and PTP is also increasingly vulnerable to cyber threats. As a response, ADVA is now empowering service providers to offer GBaaS and enable end users to address new guidelines and standards for redundant PNT architectures. GBaaS meets the latest recommendations for PNT homeland security like US Executive Order 13905. Leveraging ADVA’s aPNT+™ technology , it eliminates the risks and costs associated with GNSS dependence.

“Threats to hamper PNT capabilities are growing, and much of the world’s critical infrastructure is still without adequate protection from GNSS vulnerabilities. All of that can change when service providers are able to offer GBaaS. It’s based on our aPNT+ platform, which leverages a suite of technologies, including multi-band GNSS receivers and AI- and ML-based management software. As well as making networks more resilient against cyberattacks, our aPNT+ platform also delivers highly accurate backup when GNSS fails,” said Gil Biran, GM of Oscilloquartz, ADVA. “Now service providers can offer ADVA’s aPNT+ protection as a subscription-based service as part of their SLAs. This will enable many more timing networks to achieve very high levels of resilience and assurance. Across a wide range of industries, this will be the easiest and most flexible way to guarantee robust PNT services.”

ADVA’s GBaaS solution employs a combination of multi-layer detection, multi-source backup and fault-tolerant mitigation to render timing networks more secure. Embedded in all timing devices, ADVA’s Syncjack technology provides comprehensive and precise synchronization performance monitoring and analytics, enabling the Ensemble Sync Director network management suite to intelligently operate and prioritize multi-source timing feeds across the network. Onboard multi-band GNSS receivers boost timing accuracy and also protect against attacks like jamming and spoofing. But for those times when GNSS is either unavailable or compromised, a dispersed network of autonomous cesium atomic clocks and network backup timing feeds is always sitting on standby, ready to deliver highly accurate network timing over long periods of GNSS unavailability.

“GBaaS is a completely new way for service providers to sell critical PNT infrastructure as a service without the burden of investment and maintenance. For the first time, they can offer their customers SLAs at a range of levels that ensure the resilient and assured timing needed across time-sensitive networks and applications,” commented Nino De Falcis, senior director of business development at Oscilloquartz, ADVA. “The flexibility and protection that GBaaS affords is bad news for any malicious actors looking to attack PNT services. Service providers can now offer their customers a guarantee: When GNSS is compromised or goes offline, ADVA’s robust network of defense-in-depth PTP timing devices will be there to provide the accuracy and backup they urgently need.”

Further information on ADVA’s GBaaS solution is available in these slides: https://adva.li/gbaas-slides .

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com .

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Social Media:

https://www.facebook.com/ADVAOpticalNetworking

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye